ABL1 and breast cancer: The miR-142−/−BCR-ABL mice developed a BC-like aggressive phenotype with 100% penetrance and a significantly shorter survival compared with the miR-142+/+BCR-ABL controls, that instead remained in CP CML for their lifespans.